<DOC>
	<DOCNO>NCT03057600</DOCNO>
	<brief_summary>CX-839-007 open-label Phase 2 study combination CB-839 paclitaxel patient African ancestry non-African ancestry advance triple negative breast cancer . Multiple single-arm cohort enrol 800 mg BID CB-839 administer combination full approve dose paclitaxel .</brief_summary>
	<brief_title>Study CB-839 Combination w/ Paclitaxel Patients African Ancestry Non-African Ancestry With Advanced TNBC</brief_title>
	<detailed_description>CX-839-007 open-label Phase 2 study combination CB-839 paclitaxel patient African ancestry non-African ancestry advance triple negative breast cancer . Multiple single-arm cohort enrol 800 mg BID CB-839 administer combination full approve dose paclitaxel . Patients enrol 4 cohort , follow : - Cohort 1 : patient African ancestry 2 line prior therapy metastatic disease - Cohort 2 : patient African ancestry prior line therapy metastatic disease - Cohort 3 : cohort 1 patient non-African ancestry - Cohort 4 : cohort 2 patient non-African ancestry</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Key Meets criteria 1 4 define study cohort TNBC define ER PR negative ( &lt; 1 % ) HER2 negative ( FISH negative IHC 01+ ) Metastatic disease locallyadvanced disease amenable curative intent treatment Adequate hepatic , renal , cardiac , hematologic function ECOG performance status 01 Recovery baseline ≤ Grade 1 CTCAE ver.4.0 Key Known brain metastasis CNS cancer unless adequately treat radiotherapy and/or surgery stable ≥ 2 mo Unable receive oral medication Known hypersensitivity Cremophor®based agent Major surgery within 28 day C1D1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>African ancestry</keyword>
	<keyword>African American</keyword>
	<keyword>CB-839</keyword>
	<keyword>Glutaminase Inhibitor</keyword>
	<keyword>Glutaminase</keyword>
	<keyword>TNBC</keyword>
	<keyword>Tumor Metabolism</keyword>
	<keyword>Glutamine</keyword>
</DOC>